Clinical Trials Arena July 4, 2024
Abigail Beaney

As more regulatory bodies release guidance about the use of AI in drug and device development, the chances of not fully adhering increases.

As artificial intelligence (AI) becomes more dominant in the pharma industry, regulators have started developing guidance as to how it can be used. There are complexities however, especially for sponsors conducting global trials using AI to abide by regulation from different regions.

The US Food and Drug Administration (FDA) is in the midst of developing guidance for the use of AI and machine learning (ML) in drug development and has already released guidance on the use of AI and ML in medical devices. The European Medicines Agency (EMA) has also released draft guidance on the use of...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: AI (Artificial Intelligence), Govt Agencies, Regulations, Technology
This Is Not Broadcom’s ‘Nvidia Moment’ Yet
ChatGPT adds more PC and Mac app integrations, getting closer to piloting your computer
AI Fuels Tech Surge as Micron, Databricks and Basis Ride Wave of Growth
AI Translator Could Be ROI Boon
‘Orgs need to be ready’: AI risks and rewards for cybersecurity in 2025

Share This Article